Acute Schizophrenia Clinical Trial
Official title:
A Randomized, 6-week Double-blind, Parallel Study to Evaluate the Efficacy and the Safety of Flexible Doses of Extended Release OROS Paliperidone Compared With Olanzapine in the Treatment of Patients With Schizophrenia
Verified date | May 2010 |
Source | Xian-Janssen Pharmaceutical Ltd. |
Contact | n/a |
Is FDA regulated | No |
Health authority | China: Food and Drug Administration |
Study type | Interventional |
This is a randomized (patients are assigned different treatments based on chance),
double-blind (neither the patient nor the physician knows whether drug or placebo is being
taken, or at what dosage), active-controlled, flexible-dose, parallel group, multicenter
study. The study consists of a screening phase, a double-blind treatment phase (6 weeks) and
a safety follow-up phase (1 week).
The patients in this study will be randomized to 1 of 2 treatment groups to receive extended
release OROS paliperidone or Olanzapine once daily for the 6-week double-blind treatment
phase. Randomization will occur in a ratio of 1 (extended release OROS paliperidone) to 1
(Olanzapine). Patients must be hospitalized at least 14 days after entry. Those who receive
extended release OROS paliperidone will start at a dosage of 6 mg taken daily, dose may be
titrated up by 3mg/day every 7 days, or down rapidly based on the balance of efficacy
(effectiveness of drug) and safety/tolerability assessed by the investigator. After the
initial 7 days, dose could be flexible within 3-12mg/day. Those who receive olanzapine will
start at a dosage of 5mg taken daily, dose may be titrated up by 5mg/day every 7 days, or
down rapidly based on the balance of efficacy and safety/tolerability assessed by the
investigator. After the initial 7 days, dose could be flexible within 5-15mg/day.
Efficacy parameters include Positive and Negative Symptom Scale (PANSS) score, Clinical
Global Impression-Severity (CGI-S) and Personal and Social Performance (PSP) score per
assessment visit. The primary efficacy is the change in PANSS from baseline to the last
post-randomization assessment. Safety assessments include the adverse events, changes in
physical examination, vital signs, laboratory tests at pretreatment and posttreatment.
Status | Completed |
Enrollment | 288 |
Est. completion date | September 2007 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: - Patients (or their legally acceptable representatives) must have signed an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study - DSM-IV diagnosis of schizophrenia (295.10, 295.20, 295.30, 295.60, 295.90) at entry - Total PANSS score at screening and baseline between 60 and 120, inclusive - Female patients must be postmenopausal for at least 1 year, surgically sterile, or practicing an effective method of birth control (e.g., prescription oral contraceptives, contraceptive injections, intrauterine device, double-barrier method, contraceptive patch) before entry (and agree to continue that method throughout the study) - abstinence is not an acceptable method - have a negative urine b hCG pregnancy test at screening - Capable of self-administering study drug, or has consistent help and support available throughout the study to do this Exclusion Criteria: - A DSM-IV (Diagnostic and Statistical Manual of Mental Disorders) Axis I diagnosis other than schizophrenia - Inability to swallow the study drug whole with the aid of water (participants may not chew, divide, dissolve, or crush the study drug, as this may affect the release profile) - Previous history of a lack of response to any antipsychotic (lack of response defined as subject having had least twice a documented medical history of no clinical response despite adequate doses and durations of treatment, or the inability to tolerate effective doses) - Significant risk of suicidal or violent behavior - Injection of a depot antipsychotic within 120 days before screening, or use of paliperidone palmitate within 10 months before screening - Use of monoamine oxidase inhibitors within 4 weeks before screening - Use of antidepressants other than monoamine oxidase inhibitors or mood stabilizers (e.g., antiepileptics, lithium) within 2 weeks before screening - Received electroconvulsive therapy within 3 months before screening |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Xian-Janssen Pharmaceutical Ltd. |
China,
Fowler JA, Bettinger TL, Argo TR. Paliperidone extended-release tablets for the acute and maintenance treatment of schizophrenia. Clin Ther. 2008 Feb;30(2):231-48. doi: 10.1016/j.clinthera.2008.02.011. Review. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in total PANSS score at endpoint (6-week double-blind or last assessment after baseline) from baseline. | |||
Secondary | Changes in PANSS positive and negative scores at each assessment time point from baseline; Changes in CGI-S at each assessment time point from baseline; Changes in PSP at each assessment time point from baseline |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01668797 -
Efficacy, Safety, and Tolerability of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults With Schizophrenia
|
Phase 3 | |
Recruiting |
NCT05325645 -
Trial of Brexpiprazole Once-weekly (QW) Formulation in Patients With Acute Schizophrenia
|
Phase 3 | |
Completed |
NCT03160521 -
Study to Evaluate the Efficacy and Safety of Risperidone in Situ Microparticle (ISM)® in Patients With Acute Schizophrenia
|
Phase 3 | |
Completed |
NCT01393613 -
Efficacy Study of OPC-34712 in Adults With Acute Schizophrenia
|
Phase 3 | |
Completed |
NCT01396421 -
Study of the Effectiveness of Three Different Doses of OPC-34712 in the Treatment of Adults With Acute Schizophrenia
|
Phase 3 | |
Completed |
NCT00140166 -
Treatment of Acute Schizophrenia With Vitamin Therapy
|
Phase 4 | |
Completed |
NCT01490086 -
RP5063 in Subjects With Schizophrenia or Schizoaffective Disorder
|
Phase 2 | |
Unknown status |
NCT00838032 -
Pilot Study to Evaluate the Efficacy and Safety of Quetiapine Fumarate Instant-Release (Seroquel IR) in Controlling Agitation and Aggressive Symptoms in the Acute Treatment of Patients With Schizophrenia
|
Phase 4 |